Market capitalization | $464.94m |
Enterprise Value | $-6.93b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 17.26 |
EV/Sales (TTM) EV/Sales | -16.15 |
P/S ratio (TTM) P/S ratio | 1.08 |
P/B ratio (TTM) P/B ratio | 0.07 |
Revenue growth (TTM) Revenue growth | 1.98% |
Revenue (TTM) Revenue | $429.20m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Sinovac Biotech Ltd.:
1 Analyst has issued a forecast Sinovac Biotech Ltd.:
Jun '24 |
+/-
%
|
||
Revenue | 429 429 |
2%
2%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -262 -262 |
81%
81%
|
EBIT (Operating Income) EBIT | -392 -392 |
74%
74%
|
Net Profit | -125 -125 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.
Head office | Antigua and Barbuda |
CEO | Wei Yin |
Employees | 3,037 |
Founded | 1993 |
Website | www.sinovac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.